Congenital heart disease

Morbidity and Mortality in Adult Fontan Patients After Heart or Combined Heart-Liver Transplantation

J Am Coll CardiolPublished Retrospective cohort study

Authors' conclusion

In our multicenter cohort, post-transplant survival improved over time. Late referral after Fontan failure and markers of failing Fontan physiology, including worse functional status, lower extremity varicosities, and venovenous collaterals, were associated with post-transplant mortality.

Study context

Population
Adult Fontan patients (age ≥16 years at referral) who underwent heart transplantation (HT) or combined heart-liver transplant (CHLT), 1995–202140 CHLT
Participants
131 patients
Outcome
Post-transplant survival and predictors of post-transplant mortality
Methodological detailsmulticentre, 15 centres in the US and Canada
  • Multicentre
  • 15 centres in the US and Canada

Main finding

As reported in the abstract

Post-transplant survival

Survival at 1 year

79%

Survival at 5 years

66%

Survival at 1 year, transplant after 2010

87%

Survival at 5 years, transplant after 2010

76%

Observational data: associations, not effects.

Further findings

Predictors of decreased post-transplant survival · 1 year

EstimateP value
Time from Fontan failure to evaluationBivariate model including transplant decadeHR/year 1.23 (95% CI 1.11–1.36)P < 0.001
NYHA functional class IVBivariate model including transplant decadeHR 2.29 (95% CI 1.10–5.28)P = 0.050
Lower extremity varicositiesBivariate model including transplant decadeHR 3.92 (95% CI 1.68–9.14)P = 0.002
Venovenous collateralsBivariate model including transplant decadeHR 2.70 (95% CI 1.17–6.20)P = 0.019

Original publication

Morbidity and Mortality in Adult Fontan Patients After Heart or Combined Heart-Liver Transplantation. J Am Coll Cardiol. Published 6 June 2023. doi:10.1016/j.jacc.2023.03.422

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.